2026 BPD Singapore Biopharmaceutical Bioprocess Development Summit Banner

会议介绍

行业讲者

Professional Visitors

Special Topic

特邀活动

亮点

•以工艺与生产能力，拓展亚太尤其东南亚地区市场潜力

论坛日程

View Full Forum Schedule

9/21

BPD & XDC Gala Dinner

18:00-20:00

BPD & XDC Gala Dinner

9/22 AM

BPD Plenary Forum (Session 1)

09:00-09:05

Welcome Address

Vera Deng, Enmore BIO, Founder & CEO

09:05-09:10

Opening Remarks

Jimmy Li, WuXi XDC, CEO

09:10-09:40

Dialogue: A New Paradigm for the Globalization of China's Biopharmaceuticals: From Process Innovation to Ecosystem Collaboration

Chris Chen, WuXi Biologics, CEO

09:40-10:20

Panel Discussion: Cross-border Synergy & Bilateral Co-Development: China going Global and Southeast Asian Industrial Ecosystem under Global Supply Chain Restructure

Jimmy Li, CEO, WuXi XDC | Bo Ying, CEO, Abogen Biosciences

10:20-10:50

Tea break & Networking

10:50-11:10

Keynote Speech: From Global to Asia: Regionalization Strategy and Market Entry Pathways for Biopharmaceutical Companies

11:10-11:25

Keynote Speech: Strategic Framework and Practical Roadmap for Chinese Pharmaceutical Companies Entering the Southeast Asian Market

11:25-12:10

Panel Discussion: From Partnership to Value Co-Creation – Practical Challenges and Breakthrough Solutions for Cross-Border Pharmaceutical Collaboration between China and Southeast Asia

12:00-13:00

Lunch & Networking

9/22 PM

Novel Molecules and Innovative Therapeutics

13:00-13:20

Keynote speech: Global Technology Evolution and Analysis of Current Market Competitive Landscape of XDC

13:20-13:40

Keynote Speech: Full-Length Analytical Quality Control System for XDCs: From Process Characterization to Release Testing

13:40-14:00

Keynote: Overcoming Scale-Up Challenges in Site-Specific Conjugation: One-Stop Solutions for XDC Mass Production

14:00-14:20

Keynote Speech: Regulatory Considerations for Manufacturing and Controls of ADCs

Audrey Jia, exFDA OBP CMC reviewer; Founder of Wonderfulland Regulatory Consulting

14:20-14:40

Keynote speech: Development of TSERLIN, a tumor selective released linker-payload platform for treatment of solid tumor

SHAN, Yongqiang, SeeYondar Biotech, CEO&CSO

14:40-15:00

Tea break & Networking

15:00-15:20

Keynote Speech: mRNA Reshapes the TCE Development Paradigm

Bo Ying, CEO, Abogen Biosciences

15:20-15:40

Keynote Speech: Development Challenges and Strategies for Bispecific T-cell Engagers

15:40-16:40

Panel Discussion: Strategies and Regulatory Compliance for Global Development of Next-Generation Modalities — XDC & BsAb-TCE

16:40-17:00

Keynote Speech: From Lab to Bedside: Navigating Unmet Needs in Late-Stage Solid Tumor Treatment with Cost-Effective CAR-T Therapy

He Ting, IMUNOPHARM Technology, CEO

17:00-17:20

Keynote speech: Global Registration and Strategic Layout of Innovative iPSC Cell Therapies

Xin (Richard) YUAN, Hopstem Biopharmaceutical, Vice President of Quality

17:20-17:40

Keynote: Engineering iPSCs for Efficient Industrial-Scale Cell Therapy Manufacturing

Yen CHOO, NTU Lee Kong Chian School of Medicine, Associate Professor of Stem Cell Science and Regenerative Medicine

17:40-18:00

Keynote: CAR-T in Asia — From Clinical Validation to Commercial Scale

Cheng-Yi Jerry Kuo, UWELL BioPharma, Vice General Manager

Regulation and Market Access in Southeast Asia

13:00-13:20

Keynote speech: Commercial Effectiveness for Biopharmaceuticals Entering ASEAN

Shri Sarkar, L.E.K. Consulting, Partner

13:20-13:40

Keynote speech: Indonesia's Evolving Pharmaceutical Landscape: Regulatory Readiness and Market Access for Innovative Therapies

Shanti Marlina Sibuea, BPOM, Acting Director of Drugs, Narcotics, Psychotropics, and Precursors Production Control

13:40-14:00

Keynote Address: Advancing Cell and Gene Therapy and Clinical Research in Saudi Arabia: SFDA Regulations, Market Access, and Implementation Insights

Abdulaziz AlSayyari, BiSynergic, Managing Partner

14:00-14:20

Keynote Speech: Market Access Strategy in Singapore from an MNC Perspective

Jun Feng, J&J, APAC Market Access Director

14:20-14:40

Keynote speech: Commercializing Gene Therapy Beyond the US and Europe: Lessons from Thailand

Veerachat Petpisit, Novogenes Therapeutics, Founder

14:40-15:00

Tea break & Networking

Thermo Fisher Session

15:00-15:30

Keynote speech: Engineering Selection Pressure and Gene Integration Strategies to Accelerate Stable CHO Cell Line Development

Garima Mishra, Thermo Fisher Scientific, Field Applications Scientist Manager, Cell Culture / Cell Therapy, APJ

15:30-16:00

Keynote Address: The Next Generation of Hydrolysates: Functionally Defined Yeast Extract for CHO-Based Therapeutics and Halal-Certified Peptone for Biologics Development and Manufacturing

Chye Boon, Thermo Fisher Scientific, Global Senior Manager, Business Development, Supplements, Bioproduction Group

16:00-16:30

Keynote speech: Smarter Cell Culture Media & Process Development: From High-Throughput Screening and AI in Media Optimization to Raw Material Control and Format Economics

Gunjan Bajaj, Thermo Fisher Scientific, Senior Technical Business Development Manager, APJ Bioproduction Group

16:30-17:00

Keynote speech: Accelerating Speed to Commercialization with Single-Use Bioreactors

9/23

Cell Therapy

09:00-09:40

Panel Discussion: Global Development and Innovation Opportunities in Cell Therapy

Frank Su, TCRCure, CEO | Xiaoming Peng, Lion TCR, CEO

09:40-10:00

Keynote Speech: From Discovery to Therapeutics: Biological Advances Accelerating the Clinical Translation of MSC-sEVs

Sai Kiang Lim, Paracrine Therapeutics, Research Director

10:00-10:20

Keynote Speech: Design of In Vivo Cell Engineering Constructs

10:20-10:50

Tea break & Networking

AI for Pharma

10:50-11:10

Keynote speech: Applications of AI in Molecular Design and Target Discovery

Lipeng Lai, XtalPi, Co-Founder & CIO

11:10-11:30

Keynote Speech: Harnessing Organoids and AI for Next-Generation Targeted Drug Discovery

Haisheng Zhang, Signet Therapeutics, Founder & CEO

11:30-11:50

Keynote speech: Regulatory Compliance for AI in Pharmaceutical R&D

12:00-13:00

Lunch & Networking

Advanced Technology

13:00-13:20

Keynote Speech: Regulatory CMC Considerations for Biologics Technology Transfer

Poh Jeff, Gilead, Regulatory Affairs CMC Lead

13:20-13:40

Keynote: Key Considerations and Challenges in Bispecific Antibody Purification

Wei Zhang, BTI, Principal Scientist & Group Leader, Downstream Processing

13:40-14:00

Keynote Speech: The Role of Digitalization and Automation in Manufacturing Advanced Therapy Medicinal Products

Vipul Doshi, Zydus Lifesciences, Chief Quality and Compliance Officer, Global Pharmacovigilance head

14:00-14:20

Keynote speech: Risk-based Maintenance Change Control to Meet Global Pharma Audit Standards

Joey Low, Novartis, Senior Maintenance Engineer

14:20-14:40

Keynote speech: Nanotechnology innovation applications in Pharma industry

Deepak Hedge, Cipla (Jiangsu) Pharmaceutical, General Manager & China Site Head

14:40-15:00

Keynote Speech: The Role of Digitalization and Automation in Manufacturing Advanced Therapy Medicinal Products

Vipul Doshi, Zydus Lifesciences, Chief Quality and Compliance Officer, Global Pharmacovigilance head

15:00-16:00

Panel Discussion: Global Regulations and Best Practices for Process Characterization and Validation

Cooperation Opportunities in Southeast Asia

09:00-09:40

Panel Discussion: Southeast Asia Focus: How Innovative Biotechs Maximize R&D-Manufacturing-BD Collaboration

Andy Siow, Luye Pharma (Malaysia), Vice President APAC

09:40-10:20

Panel Discussion: Regulation and Market Access for Biologics in Singapore and Southeast Asia

Jin Shun, PharmaGend, Managing Director | Jun Feng, J&J, APAC Market Access Director | Daniel Lee, Menarini APAC, Head of Commercial | Andy Siow, Luye Pharma (Malaysia), Vice President APAC | Deepak Hedge, Cipla (Jiangsu) Pharmaceutical, General Manager & China Site Head

10:20-10:50

Tea break & Networking

10:50-11:05

Keynote Speech: Geopolitics, Supply Chains, and Market Access: Building a Resilient Biopharma Policy in India

Gaurav Arora, BioPharma Centrum, Chief Commercial Officer

11:05-11:20

Dialogue: Regulatory pathways for biologic approval in India

Gaurav Arora, BioPharma Centrum, Chief Commercial Officer | Vipul Doshi, Zydus Lifesciences, Chief Quality and Compliance Officer, Global Pharmacovigilance head

11:20-11:40

Keynote Speech: Overview of Pharmaceutical Regulatory Policies in Malaysia

11:40-12:00

Dialogue: Key Points on Regulatory Compliance in Malaysia

12:00-13:00

Lunch & Networking

Small Nucleic Acids/Peptide/mRNA/Gene Therapy

13:00-13:20

Keynote speech: Superior extra-hepatic delivery PNP Platform and Clinical Application

H. Fai Poon, CEO of Sirnaomics

13:20-13:40

Keynote: Synthesis and GMP Manufacturing of Cyclic and Specially Modified Peptides

Liu Dou, CEO, Shenzhen Oraland Pharma

13:40-14:00

Keynote speech: High-Yield Production of Vectors, Downstream Purification Processes and Critical QC Points of Gene Therapy

Claire Zhang, Grtgen, CTO

14:00-14:20

Keynote Address: Weight Management 2.0 and Beyond: Monthly Efsuglutide Alfa and a Novel Dual-Target Metabolic Pipeline

Fan Jiang, Innogen Pharmaceuticals, CFO

14:20-14:40

Keynote speech: Implementing Soft Sensors in Fermentation Processes: A Practical Approach to Real-Time Monitoring and Process Optimization

Junita Dwi Andhini, Bio Farma, QA Engineer

14:40-15:00

Keynote Speech: PEG-Free LNPs for Targeted mRNA Vaccine Delivery

Yi Yan, BTI, A*STAR, Distinguished Principal Scientist

15:00-15:20

Keynote: Harnessing Cell Surface Glycans for Therapeutics

Andre Choo, BTI, A*STAR, Deputy Executive Director

15:20-15:40

Keynote speech Competitive Landscape and Outlook for Brain-Penetrating Nucleic Acid Delivery Technologies

Tinghe Wu, P.S.K Biosciences, CEO

15:40-16:00

Keynote speech: How sponsors structure and govern CDMO engagement to ensure delivery and alignment

Special Guest

Shanti Marlina

POM Agency

Director of Drug, Narcotic, Psychotropic, and Precursor Production Control (Acting)

H. Fai Poon

CEO

Sirnaomics

Haisheng Zhang

Founder & CEO

Signet Therapeutics

Andre Choo

Deputy Executive Director

BTI, A*STAR

Yi Yan YANG

Distinguished Principal Scientist

BTI, A*STAR

Gang Qin

CEO

Gene Quantum

Poh Jeff

Regulatory Affairs CMC Lead

Gilead Sciences

Junita Dwi Andhini

QA Engineering

PT Bio Farma

Liu Dou

CEO

Oralead Pharma

Veerachat Petpisit

CEO

Nouvogenes Therapeutics

Vince Deng

Partner

Med-Fine Capital

Shri Sarkar

Partner

L.E.K. Consulting

Abdulaziz AlSayyari

Managing Partner

BiSynergic

Zhang Wei

Group Leader, Principal Scientist

BTI, A*STAR

Jin Shun

Managing Director

PharmaGend Consulting Pte Ltd